Venmax Drugs Promoter Declares No Share Encumbrances in FY26

Venmax Drugs and Pharmaceuticals Limited filed its annual promoter disclosure under SEBI SAST Regulations, confirming no encumbrance on promoter shares for FY26.
Promoter Venkat Narender Nuka declared no encumbrance on his 9,26,775 shares during the financial year ended March 31, 2026.
The disclosure is a regulatory requirement under SEBI's SAST Regulations, 2011, and was submitted to BSE on April 6, 2026.